行情

ASRT

ASRT

Assertio医疗
NASDAQ

实时行情|Nasdaq Last Sale

1.240
+0.030
+2.48%
盘后: 1.270 +0.03 +2.42% 18:36 01/17 EST
开盘
1.270
昨收
1.210
最高
1.270
最低
1.190
成交量
248.59万
成交额
--
52周最高
5.76
52周最低
0.6829
市值
1.00亿
市盈率(TTM)
-1.6213
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ASRT 新闻

  • 沪指震荡上扬 中国央行4天投放1.1万亿
  • 新浪财经.35分钟前
  • 报告:欧洲隐私数据保护法催生1.14亿欧元罚款
  • 新浪美股.4小时前
  • 澳林火重创经济命脉 当局拨7600万澳元重振旅游业
  • 中国新闻网.5小时前
  • 美债市场依然沉闷 交易员静待多家主要央行月底决策
  • 新浪美股.5小时前

更多

所属板块

制药
+0.13%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

ASRT 简况

Assertio Therapeutics, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), Cambia (diclofenac potassium for oral solution), Xartemis XR and Zipsor (diclofenac potassium). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia (PHN). Its Cambia (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.
展开

Webull提供Assertio Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。